Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | CheckMate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for RCC

Rana McKay, MD, University of California San Diego, San Diego, CA, outlines results from the Phase III CheckMate 214 trial (NCT02231749), investigating nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma (RCC). This study showed improvements in overall survival in overall patient population, and in those with intermediate and poor-risk disease. Dr McKay explains how categorized patient responses for each arm of CheckMate 214 revealed patterns of progression, where patients in the nivolumab plus ipilimumab arm more frequently exhibited new lesion progression only, particularly within the brain. Dr McKay concludes that there are differential patterns of tumor relapse at disease progression and discusses the therapeutic implications of these patterns. This interview took place during the 2021 Genitourinary Cancers Symposium.


Rana McKay, MD, has received research funding from Bayer, Pfizer and Tempus; serves on advisory boards for AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Exelixis, Janssen, Merck, Novartis, Pfizer, Sanofi and Tempus; is a consultant for Dendreon and Vividion; and serves on the molecular tumor board at Caris.